Preeti Chhabra1, Saba Rouhani2, Hannah Browne3, Pablo Peñataro Yori4,5, Mery Siguas Salas5, Maribel Paredes Olortegui5, Lawrence H Moulton2, Margaret N Kosek4,5, Jan Vinjé1. 1. Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. 3. Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA. 4. Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA. 5. Investigaciones Biomédicas, AB PRISMA, Iquitos, Peru.
Abstract
BACKGROUND: Norovirus is a leading cause of acute gastroenteritis worldwide, yet there is limited information on homotypic or heterotypic protection following natural infection to guide vaccine development. METHODS: A total of 6020 stools collected from 299 Peruvian children between 2010 and 2014 were tested by norovirus real-time reverse-transcription polymerase chain reaction followed by sequence-based genotyping. Cox proportional hazards models were used to derive adjusted hazard ratios (HRs) of infection among children with vs without prior exposure. RESULTS: Norovirus was detected in 1288 (21.3%) samples. GII.4 (26%), GII.6 (19%), and GI.3 (9%) viruses accounted for 54% of infections. Homotypic protection for GI.3 (HR, 0.35; P = .015), GI.7 (HR, 0.19; P = .022), GII.4 (HR, 0.39; P < .001), and GII.6 (HR, 0.52; P = .006) infections was observed. Hazard analysis showed that children with prior GII.4 infection exhibited heterotypic protection with a 48% reduction of subsequent GI.3 infection (HR, 0.52; P = .005). Prior exposure to GI.3, GII.2, and GII.17 infections enhanced susceptibility to subsequent infections with several other norovirus genotypes. CONCLUSIONS: Children up to 2 years of age infected with GII.4 noroviruses demonstrated both homotypic and heterotypic protection to reinfection with other genotypes. These data support the need for ongoing vaccine development efforts with GII.4 as the main component and caution the inclusion of genotypes that may enhance susceptibility to infections.
BACKGROUND: Norovirus is a leading cause of acute gastroenteritis worldwide, yet there is limited information on homotypic or heterotypic protection following natural infection to guide vaccine development. METHODS: A total of 6020 stools collected from 299 Peruvian children between 2010 and 2014 were tested by norovirus real-time reverse-transcription polymerase chain reaction followed by sequence-based genotyping. Cox proportional hazards models were used to derive adjusted hazard ratios (HRs) of infection among children with vs without prior exposure. RESULTS: Norovirus was detected in 1288 (21.3%) samples. GII.4 (26%), GII.6 (19%), and GI.3 (9%) viruses accounted for 54% of infections. Homotypic protection for GI.3 (HR, 0.35; P = .015), GI.7 (HR, 0.19; P = .022), GII.4 (HR, 0.39; P < .001), and GII.6 (HR, 0.52; P = .006) infections was observed. Hazard analysis showed that children with prior GII.4 infection exhibited heterotypic protection with a 48% reduction of subsequent GI.3 infection (HR, 0.52; P = .005). Prior exposure to GI.3, GII.2, and GII.17 infections enhanced susceptibility to subsequent infections with several other norovirus genotypes. CONCLUSIONS: Children up to 2 years of age infected with GII.4 noroviruses demonstrated both homotypic and heterotypic protection to reinfection with other genotypes. These data support the need for ongoing vaccine development efforts with GII.4 as the main component and caution the inclusion of genotypes that may enhance susceptibility to infections.
Authors: A Kroneman; H Vennema; K Deforche; H v d Avoort; S Peñaranda; M S Oberste; J Vinjé; M Koopmans Journal: J Clin Virol Date: 2011-04-21 Impact factor: 3.168
Authors: Nele Villabruna; Ray W Izquierdo-Lara; Claudia M E Schapendonk; Erwin de Bruin; Felicity Chandler; Tran Thi Nhu Thao; Brenda M Westerhuis; Janko van Beek; Louise Sigfrid; Carlo Giaquinto; Herman Goossens; Julia A Bielicki; Malte Kohns Vasconcelos; Pieter L A Fraaij; Marion P G Koopmans; Miranda de Graaf Journal: Sci Rep Date: 2022-08-22 Impact factor: 4.996
Authors: Yaoska Reyes; Fredman González; Lester Gutiérrez; Patricia Blandón; Edwing Centeno; Omar Zepeda; Christian Toval-Ruíz; Lisa C Lindesmith; Ralph S Baric; Nadja Vielot; Marta Diez-Valcarce; Jan Vinjé; Lennart Svensson; Sylvia Becker-Dreps; Johan Nordgren; Filemón Bucardo Journal: J Infect Dis Date: 2022-01-05 Impact factor: 7.759
Authors: Mark R Zweigart; Sylvia Becker-Dreps; Filemón Bucardo; Fredman González; Ralph S Baric; Lisa C Lindesmith Journal: Viruses Date: 2021-10-09 Impact factor: 5.048